Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Silvio Caccia, Roberto William Invernizzi, Alessandro Nobili & Luca Pasina. (2013) A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Therapeutics and Clinical Risk Management 9, pages 319-328.
Read now
Read now
Silvio Caccia, Luca Pasina & Alessandro Nobili. (2012) Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatric Disease and Treatment 8, pages 155-168.
Read now
Read now
Maria Rosaria A Muscatello, Antonio Bruno, Gianluca Pandolfo, Umberto Micò, Salvatore Settineri & Rocco Zoccali. (2010) Emerging treatments in the management of schizophrenia – focus on sertindole. Drug Design, Development and Therapy 4, pages 187-201.
Read now
Read now
Silvio Caccia, Luca Pasina & Alessandro Nobili. (2010) New atypical antipsychotics for schizophrenia: iloperidone. Drug Design, Development and Therapy 4, pages 33-48.
Read now
Read now
Nitin Gogtay & Judith Rapoport. (2008) Clozapine use in children and adolescents. Expert Opinion on Pharmacotherapy 9:3, pages 459-465.
Read now
Read now
Articles from other publishers (29)
Yu-Mei Wei, Xi-Jin Wang, Xiao-Dong Yang, Chuan-Sheng Wang, Li-Li Wang, Xiao-Ying Xu, Gui-Jun Zhao, Bin Li, Dao-Min Zhu, Qi Wu & Yi-Feng Shen. (2023) Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance. World Journal of Psychiatry 13:11, pages 937-948.
Crossref
Crossref
Monire Karbalaee, Melika Jameie, Mobina Amanollahi, Fateme TaghaviZanjani, Mohammadamin Parsaei, Fatemeh A. Basti, Saba Mokhtari, Kamyar Moradi, Mohammad-Reza Khodaei Ardakani & Shahin Akhondzadeh. (2023) Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Schizophrenia Research 254, pages 92-98.
Crossref
Crossref
Na Wen, Lei Chen, Xuemeng Miao, Min Zhang, Yaoyao Zhang, Jie Liu, Yao Xu, Siyu Tong, Wei Tang, Mengpu Wang, Jiahong Liu, Siyao Zhou, Xinyu Fang & Ke Zhao. (2021) Effects of High-Frequency rTMS on Negative Symptoms and Cognitive Function in Hospitalized Patients With Chronic Schizophrenia: A Double-Blind, Sham-Controlled Pilot Trial. Frontiers in Psychiatry 12.
Crossref
Crossref
László-István Bába, Melinda Kolcsár, Imre Zoltán Kun, Zsófia Ulakcsai, Fruzsina Bagaméry, Éva Szökő, Tamás Tábi & Zsolt Gáll. (2019) Effects of Cariprazine, Aripiprazole, and Olanzapine on Mouse Fibroblast Culture: Changes in Adiponectin Contents in Supernatants, Triglyceride Accumulation, and Peroxisome Proliferator-Activated Receptor-γ Expression. Medicina 55:5, pages 160.
Crossref
Crossref
Viswam Subeesh, Eswaran Maheswari, Hemendra Singh, Thomas Elsa Beulah & Ann Mary Swaroop. (2019) Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Current Drug Safety 14:1, pages 21-26.
Crossref
Crossref
Parvaneh Yazdani-Brojeni, Reo Tanoshima, Nobuko Taguchi, Facundo Garcia-Bournissen, Izhar Wallach, Myla E. Moretti, Zulfikarali Verjee & Shinya Ito. (2018) Quetiapine Excretion Into Human Breast Milk. Journal of Clinical Psychopharmacology 38:4, pages 362-364.
Crossref
Crossref
Henry A. Nasrallah, Willie Earley, Andrew J. Cutler, Yao Wang, Kaifeng Lu, István Laszlovszky, György Németh & Suresh Durgam. (2017) The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry 17:1.
Crossref
Crossref
Aanchal Rehalia, Purshottam Kumar Kaundal, Ramesh Kumar, Anju Pratap & Ajay Sharma. (2017) DOES OLANZAPINE HAVE ADVANTAGE OVER ILOPERIDONE IN EARLY AMELIORATION OF SYMPTOMS IN SCHIZOPHRENIA? A RANDOMISED PARALLEL GROUP TRIAL. Journal of Evidence Based Medicine and Healthcare 4:33, pages 1990-1995.
Crossref
Crossref
Ping-Yi Hou, Galen Chin-Lun Hung, Jia-Rong Jhong, Shang-Ying Tsai, Chiao-Chicy Chen & Chian-Jue Kuo. (2015) Risk factors for sudden cardiac death among patients with schizophrenia. Schizophrenia Research 168:1-2, pages 395-401.
Crossref
Crossref
Laura Mercolini, Maria Addolorata Saracino & Michele Protti. (2015) Current advances in biosampling for therapeutic drug monitoring of psychiatric CNS drugs. Bioanalysis 7:15, pages 1925-1942.
Crossref
Crossref
Angela L. Hill, Bin Sun & David P. McDonnell. (2014) Incidences of Extrapyramidal Symptoms in Patients with Schizophrenia after Treatment with Long-Acting Injection (Depot) or Oral Formulations of Olanzapine. Clinical Schizophrenia & Related Psychoses 7:4, pages 216-222.
Crossref
Crossref
Yael MidbariTanya EbertIra KosovMoshe KotlerAbraham WeizmanAnca Ram. (2013) Hematological and Cardiometabolic Safety of Clozapine in the Treatment of Very Early Onset Schizophrenia: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology 23:8, pages 516-521.
Crossref
Crossref
Miguel Gutiérrez Fraile, Jesús J. de la Gándara Martín & Julio Bobes García. (2013) Switching to Ziprasidone in the Clinical Practice Setting: An Open-Label Study. The International Journal of Psychiatry in Medicine 45:2, pages 125-142.
Crossref
Crossref
Marco DiBonaventura, Susan Gabriel, Leon Dupclay, Shaloo Gupta & Edward Kim. (2012) A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 12:1.
Crossref
Crossref
F. Markus Leweke, Thorsten M. Odorfer & J. Malte Bumb. 2012. Current Antipsychotics. Current Antipsychotics
165
185
.
Nathalie Ginovart & Shitij Kapur. 2012. Current Antipsychotics. Current Antipsychotics
27
52
.
David P. McDonnell, Ludmila A. Kryzhanovskaya, Fangyi Zhao, Holland C. Detke & Peter D. Feldman. (2011) Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long‐acting injection versus oral olanzapine. Human Psychopharmacology: Clinical and Experimental 26:6, pages 422-433.
Crossref
Crossref
Ariane Wohlfarth, Nicole Toepfner, Maren Hermanns-Clausen & Volker Auwärter. (2011) Sensitive quantification of clozapine and its main metabolites norclozapine and clozapine-N-oxide in serum and urine using LC-MS/MS after simple liquid–liquid extraction work-up. Analytical and Bioanalytical Chemistry 400:3, pages 737-746.
Crossref
Crossref
Mario F. JuruenaEduardo Ponde00C9; De SenaIrismar Reis De Oliveira. (2011) Sertindole in the Management of Schizophrenia. Journal of Central Nervous System Disease 3, pages JCNSD.S5729.
Crossref
Crossref
Cheng-Ta Li, Tung-Ping Su, Yuan-Hwa Chou, Ying-Chiao Lee, Mu-En Liu, Hsiao-Lun Ku, Ian-Kai Shan & Ya-Mei Bai. (2010) Symptomatic Resolution Among Chinese Patients With Schizophrenia and Associated Factors. Journal of the Formosan Medical Association 109:5, pages 378-388.
Crossref
Crossref
John M. Kane, Michael Cohen, Jun Zhao, Larry Alphs & John Panagides. (2010) Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia. Journal of Clinical Psychopharmacology 30:2, pages 106-115.
Crossref
Crossref
William V. Bobo, Jeffrey A. Stovall, Molly Knostman, Jim KoestnerRichard C. Shelton. (2010) Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data. American Journal of Health-System Pharmacy 67:1, pages 27-37.
Crossref
Crossref
Nathalie Ginovart & Shitij Kapur. 2010. The Dopamine Receptors. The Dopamine Receptors
431
477
.
Othman Amami, Mariem Siala & Afef Hachicha. (2009) Quels liens entre diabète et schizophrénie ?. L'information psychiatrique 85:1, pages 77.
Crossref
Crossref
A.J. Scheen, R. van Winkel & M.A. De Hert. (2008) Traitements neuroleptiques et troubles métaboliques. Médecine des Maladies Métaboliques 2:6, pages 593-599.
Crossref
Crossref
Andrew J. Cutler, Amir H. Kalali, Peter J. Weiden, Jennifer Hamilton & Curt D. Wolfgang. (2008) Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia. Journal of Clinical Psychopharmacology 28:2, pages S20-S28.
Crossref
Crossref
Peter J. Weiden, Andrew J. Cutler, Mihael H. Polymeropoulos & Curt D. Wolfgang. (2008) Safety Profile of Iloperidone. Journal of Clinical Psychopharmacology 28:2, pages S12-S19.
Crossref
Crossref
Thomas L. Patterson & Oscar R. Leeuwenkamp. (2008) Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophrenia Research 100:1-3, pages 108-119.
Crossref
Crossref
George H. Tse, Maria H. Warner & W. Stephen Waring. (2008) Prolonged toxicity after massive olanzapine overdose: two cases with confirmatory laboratory data. The Journal of Toxicological Sciences 33:3, pages 363-365.
Crossref
Crossref